Marijuana and its main psychoactive component, THC, exert a plethora of behavioral and autonomic effects on humans and animals.

Some of these effects are the cause of the widespread illicit use of marijuana, while others might be involved in the potential therapeutic use of this drug for the treatment of several neuronal disorders. The great majority of these effects of THC are mediated by cannabinoid receptor type 1 (CB1), which is abundantly expressed in the central nervous system. The exact anatomical and neuronal substrates of each action, however, were previously unknown.

Using an advanced genetic approach, Krisztina Monory and colleagues at the Johannes Gutenberg University Mainz discovered that specific neuronal subpopulations mediate the distinct effects of THC.

A team of researchers from China and the University of Oregon have developed an approach for neuroscientists to study how meditation might provide improvements in a person's attention and response to stress.

The study, done in China, randomly assigned college undergraduate students to 40-person experimental or control groups. The experimental group received five days of meditation training using a technique called the integrative body-mind training (IBMT). The control group got five days of relaxation training. Before and after training both groups took tests involving attention and reaction to mental stress.

A combination of drugs widely used to treat infections caused by HIV appears to stop brain damage caused by the virus as well, according to a new study.

The study involved 53 men and women with an average age of 38. The participants were given a combination of several antiretroviral drugs known as Highly Active Anti-Retroviral Therapy (HAART) for one year. Researchers tested the participants’ cerebrospinal fluid before and after treatment to see if there were elevated levels of a particular biomarker for brain injury called neurofilament light protein.

The study found 21 people had high levels of the protein, suggestive of brain damage, at the beginning of treatment.

Today's microdevices rely on external energy sources, severely limiting their mobility and autonomy in biofactory environments. New research by a group led by Dr. MinJun Kim at Drexel seeks to use a monolayer of harmless, genetically modified bacteria as a power source, which would allow future “nano-bots” to be both autonomous and self-contained.

When fabricating nanoscale motors and in developing micron-scale power sources, the actuating of fluids in microfluidic systems is usually achieved through the use of large external actuators. Dr. Kim's team is exploring the possibility of using microorganisms as a method for fabricating nanoscale elements.

A new survey(C) released by Litozin joint health reveals that men and women who aim to keep fit, could in fact, be damaging their joints. Over two thirds (68%) of all active respondents who took part in the survey had suffered from joint pain at some point.

Joint injuries seem to be a common occurrence for the nations top sports performers with David Beckham and Freddy Flintoff both recent victims.

Commissioned by LitoZin(R), a rosehip based supplement which improves joint health, the survey looked at the impact on joint health of various sporting activities amongst groups of men and women in the under 45 and over 45 age groups who all undertook 10 hours or more of light exercise a month.

Cancer patients receiving chemotherapy have not noticed a restriction in their access to treatment following the enactment of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA), despite the act's significant reduction in government reimbursement to oncologists, according to a new study led by researchers in the Duke Clinical Research Institute (DCRI).

“Critics of the MMA often said that it would reduce patients’ access to chemotherapy services, because doctors would receive 30 to 40 percent less reimbursement from the government for administering treatment,” said Kevin Schulman, M.D., director of the DCRI’s Center for Clinical and Genetic Economics, and senior investigator on the study.